- $495.69m
- $403.02m
Cabaletta Bio Inc reports results for the quarter ended in December - Earnings Summary
Brief: Cabaletta Bio Reports Q4, Full Year 2021 Financial Results
Cabaletta Bio Inc expected to post a loss of 60 cents a share - Earnings Preview
Cabaletta Bio rises on FDA fast track tag for muscle disease therapy
Brief: U.S. Food And Drug Administration Grants Cabaletta Bio Fast Track Designation For Musk-Caart
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:07 PM
U.S. STOCKS ON THE MOVE-Adobe, Under Armour, Lennar, gold stocks
U.S. RESEARCH ROUNDUP- Azek Company, Galera Therapeutics, Vivint Smart Home
U.S. STOCKS ON THE MOVE-Tesla, MGM Resorts, Planet Labs, Beyond Meat
U.S. STOCKS ON THE MOVE-Planet Labs, Beyond Meat, Galera Therapeutics, Cloudflare
NASDAQ RESUMED AT 09:42 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
U.S. STOCKS ON THE MOVE-Tesla, Weibo, Beyond Meat, pharma stocks
U.S. STOCKS ON THE MOVE-Tesla, Beyond Meat, Novavax, Chinese stocks
Brief: Cabaletta Bio Appoints Samik Basu As Chief Scientific Officer
Brief: Cabaletta Bio Reports Third Quarter 2021 Financial Results And Provides Business Update
Brief: Cabaletta Bio Reports Clinical Data From Third Dose Cohort In DesCAARTes Trial In Patients With mPV
Brief: Cabaletta Bio Reports Clinical Data From The Second Dose Cohort In Descaartes Trial In Patients With MPV
Cabaletta Bio Inc reports results for the quarter ended in June - Earnings Summary